
Newsletter
Novo Nordisk is a Danish pharmaceutical company focused on medicines for diabetes, obesity, and other serious chronic diseases.
Novo Nordisk traces its history to 1923 and is headquartered in Bagsvaerd, Denmark. Its largest products are diabetes and obesity treatments, including the semaglutide medicines Ozempic and Wegovy, along with a long line of insulins. Awiqli, its once weekly basal insulin for adults with type 2 diabetes, is one of the newer additions. The company also works in rare blood and endocrine disorders. Its medicines are prescribed by primary care physicians, endocrinologists, and obesity specialists, and reach patients through health systems, pharmacies, and payers in many countries.
Leadership as of 14 November 2026.
President and Chief Executive Officer

Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBARelated companies